Advertisement

Gastric Cancer

, Volume 22, Issue 1, pp 104–112 | Cite as

Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area

  • Boldbaatar Gantuya
  • Khasag Oyuntsetseg
  • Dashdorj Bolor
  • Yansan Erdene-Ochir
  • Ruvjir Sanduijav
  • Duger Davaadorj
  • Tegshee Tserentogtokh
  • Tomohisa Uchida
  • Yoshio YamaokaEmail author
Original Article

Abstract

Background

Mongolia has the highest mortality rate of gastric cancer. The early detection of cancer and down-staging screening for high risk patients are essential. Therefore, we aimed to validate serum markers for stratifying patients for further management.

Methods

Endoscopy and histological examination were performed to determine high risk and gastric cancer patients. Rapid urease test, culture and histological tests were performed to diagnose Helicobacter pylori infection. Serum pepsinogen (PG) I and II and anti-H. pylori IgG were measured by ELISA. Receiver Operating Characteristic analysis was used to extract the best cut-off point.

Results

Totally 752 non-cancer and 50 consecutive gastric cancer patients were involved. The corpus chronic gastritis (72%: 36/50 vs. 56.4%: 427/752), corpus atrophy (42.0%: 21/50 vs. 18.2%: 137/752) and intestinal metaplasia (IM) (64.0%: 32/50 vs. 21.5%: 162/752) were significantly higher in gastric cancer than non-cancer patients, respectively. Therefore, corpus chronic gastritis, corpus atrophy and IM were considered as high risk disease. The best serum marker to predict the high risk status was PGI/II < 3.1 (sensitivity 67.2%, specificity 61%) and PGI/II further reduced to < 2.2 (sensitivity 66%, specificity 65.1%) together with PGI < 28 ng/mL (sensitivity 70%, specificity 70%) were the best prediction for gastric cancer. The best cut-off point to diagnose H. pylori infection was anti-H. pylori IgG > 8 U/mL. Multivariate analysis showed that anti-H. pylori IgG > 8 U/mL and PGI/II < 3.1 increased risk for high risk status and PGI/II < 3.1 remained to increase risk for gastric cancer.

Conclusion

The serum diagnosis using PGI/II < 3.1 cut-off value is valuable marker to predict high risk patients for population based massive screening.

Keywords

Serum markers Gastric cancer High risk disease Helicobacter pylori Pepsinogen Mongolia 

Notes

Acknowledgements

The authors thank the study participants and wish to thank T. Matsuhisa, (A) Battulga, N. Bira, Ts. Byambajav, O. Bolor and (B) Bilguudei for collecting samples.

Author contributions

BG, KO, DD, RS and YY conceived and designed the study; BG, KO, DB, YE, TT and YY contributed by collecting samples; BG and TU performed the experiments; BG and YY contributed to analysis and interpretation; BG and YY drafted the manuscript.

Funding

This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (26640114, 15H02657 and 16H05191) (Y. Yamaoka), the Special Coordination Funds for Promoting Science and Technology from the MEXT of Japan (Y. Yamaoka), and National Institutes of Health Grants DK62813 (Y. Yamaoka). B.Gantuya is doctoral student supported by the Japanese Government (Monbukagakusho: MEXT) Scholarship Program for 2014.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

Human rights statement and informed consent

All procedures followed were in accordance with the ethical standard of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Ethical approval was obtained from the Ethics Committees of Ministry of Health, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia and Oita University Faculty of Medicine, Japan. Informed consents were obtained from all patients for their inclusion in the study.

Supplementary material

10120_2018_844_MOESM1_ESM.pdf (428 kb)
Supplementary material 1 (PDF 427 KB)

References

  1. 1.
    http://globocan.iarc.fr/. GLOBOCAN 2012 (IARC). Accessed 1 Jan 2018.
  2. 2.
    Craanen ME, Dekker W, Ferwerda J, Blok P, Tytgat GN. Early gastric cancer: a clinicopathologic study. J Clin Gastroenterol. 1991;13(3):274–83.CrossRefGoogle Scholar
  3. 3.
    Everett S, Axon A. Early gastric cancer in Europe. Gut. 1997;41(2):142–50.CrossRefGoogle Scholar
  4. 4.
    Kim GH, Bang SJ, Ende AR, Hwang JH. Is screening and surveillance for early detection of gastric cancer needed in Korean Americans? Korean J Intern Med. 2015;30(6):747.CrossRefGoogle Scholar
  5. 5.
    Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81(957):419–24.CrossRefGoogle Scholar
  6. 6.
    Choi IJ. Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc. 2014;47(6):497–503.CrossRefGoogle Scholar
  7. 7.
    Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38(4):259–67.CrossRefGoogle Scholar
  8. 8.
    Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc. 2014;47(6):478–89.CrossRefGoogle Scholar
  9. 9.
    Hosokawa O, Miyanaga T, Kaizaki Y, Hattori M, Dohden K, Ohta K, et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol. 2008;43(9):1112–5.CrossRefGoogle Scholar
  10. 10.
    Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case–control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013;8(11):e79088.CrossRefGoogle Scholar
  11. 11.
    Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20(38):13842–62.CrossRefGoogle Scholar
  12. 12.
    Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279–87.CrossRefGoogle Scholar
  13. 13.
    Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(7):405–14.CrossRefGoogle Scholar
  14. 14.
    Kuipers EJ. In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol. 2003;15(8):877–9.CrossRefGoogle Scholar
  15. 15.
    Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19(Suppl 1):S37–43.Google Scholar
  16. 16.
    Park CH, Kim EH, Jung DH, Chung H, Park JC, Shin SK, Lee SK, Lee YC. The new modified ABCD method for gastric neoplasm screening. Gastric Cancer. 2016;19(1):128–35.CrossRefGoogle Scholar
  17. 17.
    Huang Y-K, Yu J-C, Kang W-M, Ma Z-Q, Ye X, Tian S-B, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PloS One. 2015;10(11):e0142080.CrossRefGoogle Scholar
  18. 18.
    Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Prev Biomark. 2008;17(4):838–45.CrossRefGoogle Scholar
  19. 19.
    Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer. 2014;134(6):1445–57.CrossRefGoogle Scholar
  20. 20.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRefGoogle Scholar
  21. 21.
    Sharaf RN, Shergill AK, Odze RD, Krinsky ML, Fukami N, Jain R, et al. Endoscopic mucosal tissue sampling. Gastrointest Endosc. 2013;78(2):216–24.CrossRefGoogle Scholar
  22. 22.
    Uchida T, Kanada R, Tsukamoto Y, Hijiya N, Matsuura K, Yano S, et al. Immunohistochemical diagnosis of the cagA-gene genotype of Helicobacter pylori with anti-East Asian CagA-specific antibody. Cancer Sci. 2007;98(4):521–8.CrossRefGoogle Scholar
  23. 23.
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–81.CrossRefGoogle Scholar
  24. 24.
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735–40.Google Scholar
  25. 25.
    Nardone G, Rocco A, Malfertheiner P. Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther. 2004;20(3):261–70.CrossRefGoogle Scholar
  26. 26.
    Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006;20(4):651–74.CrossRefGoogle Scholar
  27. 27.
    Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8(1):8–14.CrossRefGoogle Scholar
  28. 28.
    Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol. 2010;45(1):37–44.CrossRefGoogle Scholar
  29. 29.
    Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Prev Biomark. 2006;15(11):2317–21.CrossRefGoogle Scholar
  30. 30.
    Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomark Prev. 2008;17(4):838–45.CrossRefGoogle Scholar
  31. 31.
    Terasawa T, Nishida H, Kato K, Miyashiro I, Yoshikawa T, Takaku R, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One. 2014;9(10):e109783.CrossRefGoogle Scholar
  32. 32.
    Lee S, Park JM, Park SH, Kim EH, Hahm KB. The Korean perspective of Helicobacter pylori infection: lessons from Japan policy to prevent gastric cancer. J Cancer Prev. 2013;18(2):107–12.CrossRefGoogle Scholar
  33. 33.
    Yamaoka Y, Graham DY. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol. 2014;10(8):1487–500.CrossRefGoogle Scholar
  34. 34.
    Matsuhisa T, Yamaoka Y, Uchida T, Duger D, Adiyasuren B, Khasag O, et al. Gastric mucosa in Mongolian and Japanese patients with gastric cancer and Helicobacter pylori infection. World J Gastroenterol. 2015;21(27):8408–17.CrossRefGoogle Scholar
  35. 35.
    Merchant JL, Ding L. Hedgehog signaling links chronic inflammation to gastric cancer precursor lesions. Cell Mol Gastroenterol Hepatol. 2017;3(2):201.CrossRefGoogle Scholar
  36. 36.
    Uehara T, Ma D, Yao Y, Lynch JP, Morales K, Ziober A, et al. H. pylori infection is associated with DNA damage of Lgr5-positive epithelial stem cells in the stomach of patients with gastric cancer. Dig Dis Sci. 2013;58(1):140–9.CrossRefGoogle Scholar
  37. 37.
    Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, Zendehdel N, Aliasgari A, Rakhshani N, et al. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication. BioMed Res Int. 2014;2014:7.CrossRefGoogle Scholar
  38. 38.
    Di Mario F, Moussa AM, Cavallaro LG, Caruana P, Merli R, Bertolini S, et al. Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection. Digestion. 2004;70(3):167–72.CrossRefGoogle Scholar
  39. 39.
    Pimanov SI, Makarenko EV, Voropaeva AV, Matveenko ME, Voropaev EV. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol. 2008;23(11):1666–71.CrossRefGoogle Scholar
  40. 40.
    Cao X-Y, Jia Z-F, Jin M-S, Cao D-H, Kong F, Suo J, et al. Serum pepsinogen II is a better diagnostic marker in gastric cancer. World J Gastroenterol. 2012;18(48):7357.CrossRefGoogle Scholar
  41. 41.
    Inoue M, Kobayashi S, Matsuura A, Hamajima N, Tajima K, Tominaga S. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Prev Biomark. 1998;7(3):261–3.Google Scholar
  42. 42.
    Shiota S, Thrift AP, Green L, Shah R, Verstovsek G, Rugge M, Graham DY, El-Serag HB. Clinical manifestations of helicobacter pylori–negative gastritis. Clin Gastroenterol Hepatol. 2017;15(7):1037–46.CrossRefGoogle Scholar
  43. 43.
    Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21(1):36–51.CrossRefGoogle Scholar
  44. 44.
    Zaidi SF. Helicobacter pylori associated Asian enigma: does diet deserve distinction? World J Gastrointest Oncol. 2016;8(4):341.CrossRefGoogle Scholar
  45. 45.
    Zabaleta J. Multifactorial etiology of gastric cancer. Cancer Epigenet Methods Protoc. 2012;863:411–35.CrossRefGoogle Scholar
  46. 46.
    Vasavi M, Ponnala S, Gujjari K, Boddu P, Bharatula RS, Prasad R, et al. DNA methylation in esophageal diseases including cancer: special reference to hMLH1 gene promoter status. Tumori. 2006;92(2):155–62.Google Scholar
  47. 47.
    Tsugane S, Sasazuki S, Kobayashi M, Sasaki S. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer. 2004;90(1):128.CrossRefGoogle Scholar
  48. 48.
    Song JH, Kim YS, Heo NJ, Lim JH, Yang SY, Chung GE, Kim JS. High salt intake is associated with atrophic gastritis with intestinal metaplasia. Cancer Epidemiology and Prevention Biomarkers. 2017;26(7):1133–8.CrossRefGoogle Scholar
  49. 49.
    Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Prev Biomark. 2006;15(5):872–8.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  • Boldbaatar Gantuya
    • 1
    • 2
  • Khasag Oyuntsetseg
    • 2
  • Dashdorj Bolor
    • 3
  • Yansan Erdene-Ochir
    • 4
  • Ruvjir Sanduijav
    • 5
  • Duger Davaadorj
    • 2
  • Tegshee Tserentogtokh
    • 2
  • Tomohisa Uchida
    • 6
  • Yoshio Yamaoka
    • 1
    • 7
    Email author
  1. 1.Department of Environmental and Preventive MedicineOita University Faculty of MedicineYufuJapan
  2. 2.Department of GastroenterologyMongolian National University of Medical SciencesUlaanbaatarMongolia
  3. 3.Department of EndoscopyNational Cancer CenterUlaanbaatarMongolia
  4. 4.Department of General SurgeryNational Cancer CenterUlaanbaatarMongolia
  5. 5.Department of OncologyMongolian National University of Medical SciencesUlaanbaatarMongolia
  6. 6.Department of Molecular PathologyOita University Faculty of MedicineYufuJapan
  7. 7.Department of Medicine, Gastroenterology and Hepatology SectionBaylor College of MedicineHoustonUSA

Personalised recommendations